Table 4. Comparison of mutation profiles and clinical characteristics between AML-MRC and AML-NOS.

	AML-NOS(n=52)	AML-MRC(n=43)	P
Age	46.9±21.2	52.9±20.6	.112
Sex(male/female)	33/19	28/15	.867
Complete remission	44/46(95.7%)	28/30(94.7%)	.645
Relapse	15/44(34.1%)	19/28(57.6%)	.005
Bone marrow transplantation	29/52(55.8%)	15/43(34.9%)	.042
Gene mutation
ASXL1	4(7.7%)	4(9.3%)	1.000
CEBPA	8(15.4%)	2(4.7%)	.107
DNMT3A	10(19.2%)	7(16.3%)	.709
FLT3-ITD	21(40.3%)	10(23.3%)	.076
FLT3-TKD	4(7.7%)	0(0.0%)	.124
IDH1	5(9.6%)	3(7.0%)	.725
IDH2	3(5.8%)	6(16.3%)	.177
NPM1	14(26.9%)	9(20.9%)	.497
NRAS	2(3.8%)	7(16.3%)	.074
PTPN11	1(1.9%)	3(9.3%)	.325
RUNX1	6(11.5%)	6(14.0%)	.764
SETD2	2(3.8%)	1(2.3%)	1.000
TET2	10(19.2%)	1(2.3%)	.011
TP53	0(0.0%)	3(7.0%)	.089
WT1	8(15.4%)	3(7.0%)	.335
JAK2	2(3.8%)	1(2.3%)	1.000